Compare GCTS & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | TTRX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | 126 | 2 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 107.2M |
| IPO Year | N/A | N/A |
| Metric | GCTS | TTRX |
|---|---|---|
| Price | $1.59 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.3M | 23.2K |
| Earning Date | 05-12-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,052.30 | N/A |
| Revenue Next Year | $140.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $2.57 |
| 52 Week High | $2.47 | $5.98 |
| Indicator | GCTS | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.27 | 61.83 |
| Support Level | $1.39 | $3.55 |
| Resistance Level | $1.80 | $4.01 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 89.47 | 95.45 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.